Pancreatic Cancer Center

Where to Find Us

Our experts aim to transform the prevention, early detection, and treatment of pancreatic cancer for patients.

We have developed a new paradigm for approaching the research and treatment of pancreatic cancer and noncancerous pancreatic tumors. We put patients at the center of every healthcare decision, and have an unparalleled collaboration among multiple types of experienced physicians and researchers—in the laboratory and the clinic. We believe this is the key to finding innovative and effective therapies that bring new hope to pancreatic cancer patients.

Our experts at NYU Langone’s Perlmutter Cancer Center work together to carry out groundbreaking basic and translational research and to provide a large portfolio of comprehensive clinical trials. At the same time, we provide individualized patient care, with a focus on transforming the early detection and prevention of pancreatic cancer, as well as the treatment of this condition. Our goal at the Pancreatic Cancer Center is to increase the 5-year survival rate for pancreatic cancer to 50 percent within the next 10 years.

Our dedicated multidisciplinary team includes medical oncologists, pancreatic surgeons, radiation oncologists, gastroenterologists, pathologists, radiologists, and experts who are trained in the most advanced molecular profiling and genetic testing.

Every patient’s individual medical needs are discussed at a weekly meeting, and a personalized treatment plan is developed to ensure that you receive the care and treatment that’s best for you. Our services include the most advanced techniques in endoscopic and surgical treatments and the latest medical therapies. Through support groups and counseling, we provide psychological assistance to patients and their caregivers during treatment.

We also offer innovative medical and surgical approaches to treat patients with locally advanced pancreatic cancer, a type of cancer that has invaded or advanced toward blood vessels and other tissues around the pancreas. Led by Diane M. Simeone, MD, and Alec J. Megibow, MD, our team has developed imaging guidelines for the diagnosis of locally advanced pancreatic cancer, which are currently being used as the national standard of care.

Treatment options include chemotherapy before surgery, called neoadjuvant chemotherapy, which is designed to shrink the tumor and make it easier to remove. Dr. Simeone and Theodore H. Welling, MD, have performed more than 100 surgical procedures after chemotherapy for these types of pancreatic cancer.

Make an Appointment

We are available to respond to any questions or concerns that you might have and to help you make an appointment. Often, pancreatic cancer has few early symptoms and is therefore diagnosed at an advanced stage. For this reason, we make sure that you can be seen by one of our doctors within one week of your request for an appointment.

Our Leadership

Dr. Simeone is an internationally recognized expert in pancreatic cancer. She is also the associate director for translational research at NYU Langone’s Perlmutter Cancer Center. She provides state-of-the-art surgical care for people with pancreatic tumors. Her research focuses on early detection and new therapies for pancreatic cancer, with the goal of improving patient survival. She studies the molecular events that lead to pancreatic cancer and strives to expedite the progression of laboratory research to clinical practice. She also leads a clinical research program in the early detection of pancreatic cancer in people who are at high risk.